BACKGROUND: Better outcomes have been observed in patients with acute unprovoked than provoked pulmonary embolism (PE). Prognostic biomarkers were studied in heterogeneous patient population and were not verified in patients with unprovoked PE.
A cute pulmonary embolism (PE) is a potentially life-threatening disease. Indeed, 30-day mortality rates in patients stratified by the European Society of Cardiology (ESC) classification into high-, intermediate-high-, and intermediatelow-risk groups were found to be 22%, 7.7%, and 6.0%, respectively. [1] Early identification of patients at high risk of poor outcomes may improve the survival rate of patients with acute PE. Although the PE severity index (PESI) remains the most validated tool predicting short-term mortality in patients with acute PE, this index includes 11 variables and is somewhat complex to calculate, making it less useful in clinical practice. Moreover, patients with unprovoked PE were found to have a more favorable outcome than patients with provoked PE, [2, 3] suggesting the need to validate risk classification systems in patients with unprovoked PE.
Biomarkers such as brain natriuretic peptide (BNP), troponin, and heart-type fatty acid-binding protein may help in stratifying risk and determining prognosis in patients with acute PE. However, these biomarkers have been studied in highly heterogeneous patient populations with various provoking risk factors and have not been verified as useful in patients with unprovoked PE. This study therefore sought to identify blood biomarkers useful in assessing prognosis, including adverse outcomes, in patients with acute unprovoked PE.
Methods
T h i s r e t r o s p e c t i v e s t u d y i n c l u d e d p a t i e n t s aged ≥18 years with unprovoked acute PE diagnosed from January 2010 to December 2017 at a 2700-bed university-affiliated tertiary referral center in Seoul, South Korea. Patients were diagnosed with unprovoked PE if they did not have known risk factors for PE. That is, patients with temporary (e.g., surgery, hospitalization due to acute illness, or cesarean section within 3 months; or estrogen therapy, pregnancy, or leg injury within 2 months) or persistent (cancer or inflammatory bowel disease) risk factors were excluded. [4] Patients who were referred to our hospital after the start of treatment at outside hospital were also excluded because it is difficult to review the initial manifestation. All clinical, radiologic, and laboratory data were retrospectively collected from medical records. PE was confirmed by spiral computed tomography or by ventilation-perfusion lung scanning, indicating a high probability of PE. Adverse composite outcomes included mortality and clinical conditions that would result in death unless treated with following strategies recommended by the ESC guidelines: [5] (1) thrombolysis, (2) thrombectomy, or (3) extracorporeal membrane oxygenation (ECMO).
This study was conducted in accordance with the amended Declaration of Helsinki and was approved by the Institutional Review Board of Asan Medical Center (approval number: 2018-0201), which waived the requirement for informed consent due to the retrospective nature of the study. The study outcomes will not affect the future management of the patients, and the authors declare that the patient's personal data have been secured.
Risk groups based on early mortality rate were stratified according to the 2014 ESC guidelines and PESI and simplified PESI scores. [5, 6] Patients were classified as being at high, intermediate-high, intermediate-low, or low risk, according to the ESC classification. Patients were classified by a numeric number and/or class from I to V (PESI alone) according to the PESI and simplified PESI. Risk-adjusted therapy was administered based on these risk classifications.
Venous blood samples were collected at the first visit to the clinic before anticoagulation was administered. Complete blood count was measured using a Sysmex XE-2100 automated hematology analyzer (Sysmex, Kobe, Japan). Plasma glucose was measured by the hexokinase method using an autoanalyzer (Toshiba, Tokyo, Japan). Serum uric acid was measured enzymatically using an automatic biochemistry analyzer (Cobas ® 8000 modular analyzer series; Roche Diagnostics GmbH, Vienna, Austria). BNP concentration was estimated using a chemiluminescence immunoassay (ADVIA Centaur; Bayer Diagnostics, Tarrytown, NY, USA). Plasma D-dimer levels were determined by an enzyme-linked immunosorbent assay method using Asserachrom D-Di (Diagnostica Stago, Asnieres-sur-Seine, France). To identify blood biomarkers associated with high-risk PE, the levels of these biomarkers were compared in patients stratified according to the ESC risk classification and the occurrence or nonoccurrence of adverse composite outcomes.
Categorical variables were reported as n (%) and compared using the Chi-square test. Continuously measured parameters were reported as means ± standard deviation or median (interquartile range [IQR]) and were compared using Student's t-test or the Mann-Whitney U-test.
Risk factors associated with the adverse composite outcome were determined by logistic regression analysis using the backward stepwise conditional method. The variables assessed significant in univariate regression analysis were entered as independent variables in multivariate logistic regression model. Next, receiver operating characteristic (ROC) analysis was performed and the area under the curve (AUC) was determined to test the performance of blood biomarker model and preexisting risk model, with respect to predicting the likelihood of adverse composite outcomes. Statistical differences in AUC values among models were calculated using DeLong's test. [7] All statistical analyses were performed using SPSS 21.0 (IBM Corporation, Armonk, NY, USA) and MedCalc Statistical Software version 18.5 (MedCalc Software bvba, Ostend, Belgium), with statistical significance defined as a P < 0.05.
Results
Between January 2010 and December 2017, 1561 patients were diagnosed with acute PE. Of these, 1210 patients with provoked PE and 86 with unprovoked PE who were referred to our hospital after the start of treatment at another hospital were excluded. This study therefore included 265 patients (48.7% male), of median age 66.0 (IQR 52, 75) years, with unprovoked acute PE [ Table 1 ]. Before being diagnosed with PE during this study period, 17 had a history of deep vein thrombosis (DVT) and 20 had a history of PE. DVT was evaluated in 87.5% of patients, with 57.4% confirmed as having DVT. Adverse composite outcomes occurred in 20 (7.5%) patients; of these, 16 underwent thrombolysis, two underwent embolectomy, and two were supported with ECMO followed by thrombolysis or embolectomy. There were no in-hospital deaths. Patients who developed adverse composite outcome had significantly higher WBC counts and significantly higher concentrations of hemoglobin, uric acid, glucose, LD, troponin I, and BNP than patients who did not develop adverse composite outcomes [ Table 3 ]. Univariate logistic regression analysis showed that hemoglobin, uric acid, glucose, CK-MB, and BNP concentrations were significantly associated with the adverse composite outcome. The ESC risk classification also showed significant relationship (odds ratio [OR]: 2.878, 95% confidence interval [CI]: 1.626-5.094, P < 0.001) with adverse Table 4 ]. By contrast, PESI score (OR: 1.009, 95% CI: 0.993-1.026, P = 0.261) and simplified PESI score (OR: 1.495, 95% CI 0.920-2.431, P = 0.105) were not significant predictors of adverse composite outcomes in univariate logistic regression analysis.
The ability of each prognostic model to predict adverse composite outcomes is shown in Table 5 and Figure 1 . The ROC curve for a biomarker model including hemoglobin, uric acid, and glucose concentrations showed the highest prognostic accuracy for adverse composite outcomes, with an AUC of 0.806 (95% CI: 0.702-0.911, P < 0.001), which was significantly better than that of PESI (AUC: 0.517, 95% CI: 0.376-0.657, P = 0.0001) or simplified PESI (AUC: 0.598, 95% CI: 0.467-0.728, P = 0.0009), and similar to that of ESC risk classification (AUC: 0.686, 95% CI: 0.548-0.824, P = 0.0659).
Discussion
Few studies to date have evaluated the ability of blood biomarkers to predict risk and outcome in patients with unprovoked acute PE. This study found that, in addition to BNP and troponin I concentrations, WBC counts, and hemoglobin, uric acid, glucose, and LD concentrations were useful in predicting adverse composite outcomes in patients with unprovoked acute PE. function and cardiac biomarkers, which may better reflect hemodynamic significance that is important in determining thrombolysis, thrombectomy, or ECMO.
Venous thromboembolism (VTE) and cardiovascular disease have been found to share common risk factors. [8] For example, elevated uric acid concentration and hyperglycemia are risk factors for several cardiovascular diseases and may also be risk factors for VTE. Several studies report that the development of VTE is associated with uric acid levels or gout, [9, 10] possibly due to the pro-oxidant and pro-inflammatory effects of uric acid and its induction of endothelial dysfunction. [11] Previous studies have also reported that elevated uric acid was predictive of PE severity [12] and short-term mortality. [13] Uric acid, a byproduct of purine catabolism, is increased under the hypoxic conditions associated with diseases, such as obstructive sleep apnea, chronic obstructive pulmonary disease, and congestive heart failure. [14] [15] [16] In addition, uric acid levels may correlate negatively with cardiac output and positively with mean pulmonary arterial pressure in patients with PE and primary pulmonary hypertension. [12, 17] These findings suggest that hypoxia, pulmonary hypertension, and decreased cardiac output in PE may elevate uric acid level, which correlates with the severity of PE.
Hyperglycemia was another cardiovascular risk factor found in this study to be a significant risk factor for adverse composite outcome. Several studies have reported relationships between hyperglycemia and acute PE development or mortality, [18, 19] with mortality rates higher in individuals without than with diabetes. [19] Hyperglycemia can activate the coagulation system, reduce fibrinolysis, and reduce the protective glycocalyx layer by directly affecting the endothelium; this, in turn, is often accompanied by hyperinsulinemia, resulting in an even stronger hypercoagulable state. [20] Hyperglycemia may also result from the release of stress hormones, such as catecholamines, growth hormone, and cortisol in acute stress conditions. Determining the causal relationship between hyperglycemia and PE requires a determination of the history of previous diabetes mellitus (DM) and long-term blood glucose levels before and after the acute stage of PE.
Hemoglobin was significantly higher (15.1 ± 2.2 g/dL) in patients with adverse composite outcomes and had an OR of 1.438 for the development of adverse outcomes. Increases in hematocrit may increase blood viscosity, [21] platelet function (adhesiveness and reactivity), [22, 23] and thrombin activity and concentration. [24] Although there was an opposite result that low hemoglobin concentration was associated with high mortality rates in patients with PE, [25] the cohort in that study was heterogeneous, with many patients in the low hemoglobin group having cancer, surgery, or bleeding, and the possible causes of anemia were not evaluated.
This study had several limitations. First, it was a retrospective observational study in a single tertiary center. All data were collected from patients' medical records, making them susceptible to bias in data selection and analysis. Second, we cannot explain why patients with unprovoked PE had a better prognosis and different risk factors than patients with provoked PE. The absence of several comorbidities in patients with unprovoked PE may have contributed to their better prognosis. In addition, advanced treatments, such as thrombolysis, embolectomy, and ECMO, were readily available to patients in our medical center but may be less available to patients in primary and secondary care hospitals. Finally, we could not determine whether the above-described biomarkers are causes or effects of PE. Further studies are needed to validate these biomarkers.
Conclusions
The biomarker model including hemoglobin, uric acid, and glucose has good prognostic performance comparable to ESC risk classification while PESI or simplified PESI score was not useful in unprovoked acute PE. Measurement of these biomarkers is very useful in real clinical practice, as these assays are relatively noninvasive, cost-effective, and easily available.
